The DESTINY-PanTumor01 phase II basket trial involves patients with unresectable/metastatic solid tumors with HER2 mutations, and recent data from a primary analysis of 20 breast cancer patients showed an encouraging ORR of 50% [28]. This evidence concerns the gene ERBB2 and breast cancer.